Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055.

The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF.

The topline results demonstrate that ISM001-055 is safe, well-tolerated, exhibits a favourable pharmacokinetics (PK) profile, and has encouraging clinical efficacy as measured by improvement in forced vital capacity (FVC) at 12 weeks.

“I am very impressed by the positive results observed in IPF patients treated with ISM001-055, particularly the encouraging improvement in FVC. It not only reflects ISM001-055’s potential to slow disease progression but also suggests its capability to stop or even reverse it,” said Zuojun Xu, Professor of Peking Union Medical College and the principal investigator. “AI, as an advanced technology, is already playing a crucial role in many aspects of medical practice, including drug discovery and clinical research, and we expect to see the real clinical benefits it brings to patients.”

Results show disease-modifying potential

Key findings from the ISM001-055 Phase IIa clinical trial topline results include:

  • ISM001-055 was well-tolerated across all dosing groups. The majority of the drug-related adverse events were mild or moderate in severity.
  • The PK profile of ISM001-055 in IPF patients was in line with the results of Phase I studies in healthy subjects with a half-life of 7-12 hours. In addition, a higher proportional exposure was observed at 60mg QD compared with 30mg BID.
  • Patients who received ISM001-055 demonstrated a dose-dependent improvement in lung function for all doses by the 12 weeks of the trial, with a 98.4mL mean improvement in forced vital capacity (FVC) from baseline at the highest dose of 60mg QD as compared to a mean decline in FVC change from baseline of -62.3mL for patients in the placebo group.
  • Patients who received ISM001-055 also showed a similar dose-dependent trend in percent predicted forced vital capacity (ppFVC), with a 3.05% mean improvement in ppFVC from baseline at the highest dose of 60mg QD as compared to a mean decline in ppFVC of -1.84% for patients in the placebo group.
  • Improvement in quality of life (QoL) and functional measures were also evaluated by change in Leicester Cough Questionnaire (LCQ) score from week 0 to week 12, with a meaningful 2-point improvement in LCQ total score in the highest dose of 60mg QD group compared to the placebo group by week 12.

“The dose-dependent improvement in FVC in IPF patients treated with ISM001-055 compared to those treated with placebo suggest ISM001-055 may play a role in both the prevention of progression of IPF as well as disease regression, thus highlighting the disease-modifying potential. Future studies will help delineate these benefits further with the hope that ISM001-055 may transform the current treatment paradigm,” said Dr Carol Satler, Vice President of Clinical Development.

Diana Spencer, Senior Digital Content Editor, DDW